News & Events

News, industry insights and noteworthy events.

At Tanner, we take pride in the success of our partnerships and acknowledge the milestones achieved in pursuing our mission; to improve lives by increasing access to medicines around the world.

For media or press inquiries, please email us.

Contact Us

All Articles

  1. Epimune and Tanner Pharma Group enter into Distribution Partnership for Latin America

    Berlin, 27 January 2021 – Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro…

    Read More
  2. Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)

    SALT LAKE CITY and CHARLOTTE, N.C., Dec. 1, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, announced today that they have launched a global…

    Read More
  3. Sending Wilson home: A story of perseverance and teamwork

    (Repost from ZNM) Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner…

    Read More
  4. 5 Things to Consider When Commercializing a New Drug in Latin America

    Some of the over 8,000 drugs in development are poised to be breakthrough treatments that will substantially improve or save patients’ lives. The pharmaceutical companies developing these revolutionary medications have at least two goals: ensuring their research investment is profitable and making sure the drug is available to help any person who needs it.   If your company is developing a new drug, you may be ready to achieve these goals in your existing or developed markets, but what about new ones, like Latin America and other emerging markets? If you haven’t done it before, that’s an entirely…

    Read More
  5. The Value of Real-World Data from Global Expanded Access Programs for Rare Diseases

    John Lagus, Tanner’s EVP of Business Development focusing on managed access programs, recently spoke at MarketandMarkets’ Digital Event on Orphan Drugs and Rare Diseases about the value of real-world data (RWD) from expanded access programs (EAPs) for rare diseases. Here are a few highlights from his talk.  Years ago, while in Botswana, John Lagus met a woman who offered her life savings to purchase critical medicine for her daughter. This conversation stayed with…

    Read More
  6. 3 Insights for Effective Comparator Sourcing

    Whether you’re a global pharma or a biotech start-up, every clinical trial will entail overcoming challenges with sourcing, packaging, and the logistics of clinical materials. Choosing the right partner provides you with flexibility and risk mitigation, ensuring you can choose the most cost-effective solution, and avoid delays. Here are some of the key factors to…

    Read More
  7. Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®

    Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®   MILAN, ITALY and CHARLOTTE, USA – Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries. The agreement names Tanner Pharma…

    Read More
  8. Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea® (micellular paclitaxel)

    SALT LAKE CITY and CHARLOTTE, N.C., July 27, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named…

    Read More
  9. Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

    Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc. May 12, 2020 For Immediate Release Contact: Telephone: 704-552-8407 Email: versacloz@tannerpharma.com   CHARLOTTE, N.C. – Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Tasman Pharma Inc. The agreement names Tanner as a…

    Read More
  10. Increasing Access for Rare Disease Patients Globally

    Patients who suffer from rare diseases often lack access to innovative treatment options because the manufacturer of the medicine cannot justify the investment in registering and commercializing the medicine in countries where patient populations are low.  Managed Access Programs provide  manufacturers of innovative medicines for rare diseases a cost-effective option to provide patients access in countries where the medicine is not commercially available.  If a physician chooses to prescribe such…

    Read More
  11. Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

    PERTH, Australia & CHARLOTTE, N.C., June 15, 2020 –-(BUSINESS WIRE)–Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global named patient program for AndroFeme® 1 testosterone cream for women. “Partnering with Tanner gives women access to a female specific testosterone treatment for HSDD which is experienced by one in every three…

    Read More
  12. Hiring of Jonathan Bracey as Managing Director – UK

    For Immediate Release Contact: Joshua Cooper Tanner Pharma Group 704.552.8408 jcooper@tannerpharma.com CHARLOTTE, N.C., December 1, 2015 – Tanner Pharma Group is pleased to announce the hiring of Jonathan Bracey as Managing Director – UK, effective 1 December, 2015. Mr. Bracey brings two decades of management experience, making him an optimal candidate in leading the recently…

    Read More
  13. Tanner Pharma Group to Present at Bourne Partners 5th Annual Global Healthcare Executive Summit

    Joshua Cooper to Moderate Healthcare Services Panel, “Changing Dynamics of Pharma Services”   CHARLOTTE, N.C., August 21, 2015 – Tanner Pharma Group will be largely showcased at the upcoming Bourne Partners Fifth Annual Global Healthcare Executive Summit on September 3, in Charlotte, North Carolina. The conference, held at the internationally renowned Mint Museum, will feature…

    Read More
  14. Max Global Experience: Uganda

    Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s 2018 “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa. In August, Banks Bourne, Founder & Chairman of Tanner Pharma Group / CEO of Bourne Partners, and Rob Keel, Director of…

    Read More
  15. Tanner Pharma Group Executives to Present at 2015 BIO International

    Presentations to Focus on Enhancing Access and Commercial Success in Challenging International Markets with Minimal Risk and Investment CHARLOTTE, N.C. – Top executives from Tanner Pharma Group will speak at the largest life-science conference in the world, the 2015 BIO International Convention, scheduled for June 15-18 in Philadelphia. The presentations will provide key insights into…

    Read More
  16. Tanner Pharma Group Formed From Merger of Tanner Pharmaceuticals & BurnsAdler Pharmaceuticals

    New Firm’s Complementary Divisions Provide Single-Point Solutions for Clients Seeking Clinical Trial Sourcing, Global Access Programmes and Commercialization Expertise in Challenging Global Markets  CHARLOTTE, N.C. – Tanner Pharmaceuticals, Inc., a global pharma services company that provides access to pharmaceuticals through Global Access Programmes and Clinical Trials Sourcing, and BurnsAdler Pharmaceuticals, a specialty pharmaceutical company that licenses…

    Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.